IDiyas

For the Inventor, By the Inventor

Kanagawa, Japan

Yoshiteru Ito

USPTO Granted Patents = 21 

 

 

Average Co-Inventor Count = 9.6

ph-index = 2

Forward Citations = 36(Granted Patents)


Location History:

  • Fujisawa, JP (2020 - 2022)
  • Kanagawa, JP (2016 - 2024)

Company Filing History:

goldMedal21 out of 1,177 
 
Takeda Pharmaceutical Company Limited
 patents

Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):
1. 12448377 - Heterocyclic compound (2025-10-21),
2. 12421188 - Heterocyclic compound and use thereof (2025-09-23),
3. 12415782 - Heterocyclic compound and use thereof (2025-09-16),
4. 12404237 - Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1'-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives (2025-09-02),
5. 12358879 - Heterocyclic compound (2025-07-15),
6. 12152027 - Heterocyclic compound (2024-11-26),
7. 12091410 - Heterocyclic compound (2024-09-17),
8. 12071434 - Heterocyclic compound (2024-08-27),
9. 11987586 - Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists (2024-05-21),
10. 11897879 - Heterocyclic compound (2024-02-13),
11. 11655241 - Heterocyclic compound and use thereof (2023-05-23),
12. 11440883 - Heterocyclic compound and use thereof (2022-09-13),
13. 11390634 - Fused heterocyclic compound (2022-07-19),
14. 11319286 - Heterocyclic compound and application thereof (2022-05-03),
15. 11230545 - Heterocyclic compound (2022-01-25),

Title: Innovations of Yoshiteru Ito

Introduction

Yoshiteru Ito is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors in the brain. With a total of 20 patents to his name, his work has the potential to impact the treatment of various sleep disorders.

Latest Patents

Among his latest patents is a heterocyclic compound that exhibits orexin type 2 receptor agonist activity. This invention is particularly noteworthy as it provides a potential agent for the prophylaxis or treatment of narcolepsy. The compound is represented by a specific formula, which is detailed in the patent specification. This innovation highlights the ongoing research and development efforts in addressing sleep-related issues.

Career Highlights

Yoshiteru Ito is currently associated with Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His role at Takeda allows him to collaborate with other experts in the field and contribute to groundbreaking research. His extensive experience and innovative mindset have positioned him as a key player in the pharmaceutical industry.

Collaborations

Yoshiteru Ito has worked alongside talented colleagues such as Tatsuki Koike and Keisuke Imamura. Their collaborative efforts have led to advancements in the understanding and treatment of sleep disorders, showcasing the importance of teamwork in scientific research.

Conclusion

Yoshiteru Ito's contributions to the field of pharmaceuticals, particularly through his innovative patents, demonstrate his commitment to improving healthcare solutions. His work continues to pave the way for new treatments that can enhance the quality of life for individuals suffering from narcolepsy and other sleep disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…